SCHEMBL3029925

SCHEMBL3029925

COc1cc(C#N)cc(Oc2c(Cl)ccc(CNC(=O)c3[nH]c(N)nc3Cl)c2F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
WDR5 P61964 3/20 0.34
PTGES O14684 2/20 0.34
SCN9A Q15858 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
CHRM4 P08173 2/20 0.34
MMP13 P45452 1/20 0.34
MAPK8 P45983 1/20 0.34
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34
RORC P51449 1/20 0.34
GSK3B P49841 2/20 0.33
KIT P10721 1/20 0.33
RPS6KB1 P23443 1/20 0.33
AKT1 P31749 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL13560564 0.95 CYP3A4 (0.40) CYP3A4CYP2C9CYP2C19WDR5PTGES
SCHEMBL3027058 0.93 CYP3A4 (0.47) CYP3A4CYP2C9CYP2C19PTGESMAPK8
SCHEMBL3017541 0.92 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19PTGESSCN9A
SCHEMBL13638760 0.92 PTGES (0.37) CYP3A4CYP2C9CYP2C19WDR5PTGES
SCHEMBL13634086 0.91 CYP3A4 (0.46) CYP3A4CYP2C9CYP2C19WDR5PTGES
SCHEMBL3032295 0.90 CYP3A4 (0.40) CYP3A4CYP2C9CYP2C19PTGESRORC
Trifluoroacetic Acid SCHEMBL3022995 0.88 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3017035 0.88 CYP3A4 (0.39) CYP3A4CYP2C9CYP2C19PTGESEPHX2
Trifluoroacetic Acid SCHEMBL3025136 0.88 CYP3A4 (0.39) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3642544 0.87 CYP3A4 (0.49) CYP3A4CYP2C9CYP2C19PTGESSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US claimed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US claimed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP claimed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO claimed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP3A4 169/4885CYP2C9 720/4885CYP2C19 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.